Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG-89894 in Advanced Solid Tumors
NCT06568614Phase 1Terminated
- Sponsor
- BeOne Medicines
- Start
- Oct 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of SYH2039 in solid tumor (2 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participants with Adverse Events and Serious Adverse Events at 24 months, Maximum Tolerated Dose or Maximum Administered Dose at 1 month and 3 more. Started Oct 2024; status: terminated.
02
Drugs
SYH2039
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06568614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06568614.